BACKGROUND: An alternative reduced-toxicity conditioning regimen for allogeneic transplantation, based on treosulfan and fludarabine, has recently been identified. The rationale for this study was to investigate the efficacy and safety of this regimen prospectively in patients with a primary myelodysplastic syndrome. DESIGN AND METHODS: A total of 45 patients with primary myelodysplastic syndromes were conditioned with 3×14 g/m(2) treosulfan and 5×30 mg/m(2) fludarabine followed by allogeneic hematopoietic stem cell transplantation. Subtypes of myelodysplastic syndromes were refractory anemia with excess blasts-2 (44%), refractory cytopenia with multilineage dysplasia (27%), refractory anemia (9%), refractory anemia with ringed sideroblasts (4%), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (4%), refractory anemia with excess blasts-1 (2%), and myelodysplastic syndrome with isolated del (5q) (2%). The myelodysplastic syndrome was unclassified in 7% of the patients. Forty-seven percent of the patients had a favorable karyotype, 29% an unfavorable one, and 18% an intermediate karyotype. Patients were evaluated for engraftment, adverse events, graft-versus-host disease, non-relapse mortality, relapse incidence, overall survival and disease-free survival. RESULTS: All but one patient showed primary engraftment of neutrophils after a median of 17 days. Non-hematologic adverse events of grade III-IV in severity included mainly infections and gastrointestinal symptoms (80% and 22% of the patients, respectively). Acute graft-versus-host disease grade II-IV developed in 24%, and extensive chronic graft-versus-host disease in 28% of the patients. After a median follow-up of 780 days, the 2-year overall and disease-free survival estimates were 71% and 67%, respectively. The 2-year cumulative incidences of non-relapse mortality and relapse were 17% and 16%, respectively. CONCLUSIONS: Our safety and efficacy data suggest that treosulfan-based conditioning therapy is a promising treatment option for patients with myelodysplastic syndromes. clinicaltrials.gov identifier: NCT01062490.
BACKGROUND: An alternative reduced-toxicity conditioning regimen for allogeneic transplantation, based on treosulfan and fludarabine, has recently been identified. The rationale for this study was to investigate the efficacy and safety of this regimen prospectively in patients with a primary myelodysplastic syndrome. DESIGN AND METHODS: A total of 45 patients with primary myelodysplastic syndromes were conditioned with 3×14 g/m(2) treosulfan and 5×30 mg/m(2) fludarabine followed by allogeneic hematopoietic stem cell transplantation. Subtypes of myelodysplastic syndromes were refractory anemia with excess blasts-2 (44%), refractory cytopenia with multilineage dysplasia (27%), refractory anemia (9%), refractory anemia with ringed sideroblasts (4%), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (4%), refractory anemia with excess blasts-1 (2%), and myelodysplastic syndrome with isolated del (5q) (2%). The myelodysplastic syndrome was unclassified in 7% of the patients. Forty-seven percent of the patients had a favorable karyotype, 29% an unfavorable one, and 18% an intermediate karyotype. Patients were evaluated for engraftment, adverse events, graft-versus-host disease, non-relapse mortality, relapse incidence, overall survival and disease-free survival. RESULTS: All but one patient showed primary engraftment of neutrophils after a median of 17 days. Non-hematologic adverse events of grade III-IV in severity included mainly infections and gastrointestinal symptoms (80% and 22% of the patients, respectively). Acute graft-versus-host disease grade II-IV developed in 24%, and extensive chronic graft-versus-host disease in 28% of the patients. After a median follow-up of 780 days, the 2-year overall and disease-free survival estimates were 71% and 67%, respectively. The 2-year cumulative incidences of non-relapse mortality and relapse were 17% and 16%, respectively. CONCLUSIONS: Our safety and efficacy data suggest that treosulfan-based conditioning therapy is a promising treatment option for patients with myelodysplastic syndromes. clinicaltrials.gov identifier: NCT01062490.
Authors: B D Cheson; J M Bennett; H Kantarjian; A Pinto; C A Schiffer; S D Nimer; B Löwenberg; M Beran; T M de Witte; R M Stone; M Mittelman; G F Sanz; P W Wijermans; S Gore; P L Greenberg Journal: Blood Date: 2000-12-01 Impact factor: 22.113
Authors: H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas Journal: Transplantation Date: 1974-10 Impact factor: 4.939
Authors: Mary A Slatter; Kanchan Rao; Persis Amrolia; Terry Flood; Mario Abinun; Sophie Hambleton; Zohreh Nademi; Nick Goulden; Graham Davies; Waseem Qasim; Hubert B Gaspar; Andrew Cant; Andrew R Gennery; Paul Veys Journal: Blood Date: 2011-02-16 Impact factor: 22.113
Authors: Rob E Ploemacher; Kevin W Johnson; Elwin J C Rombouts; Kenol Etienne; G Robbin Westerhof; Joachim Baumgart; Mary E White-Scharf; Julian D Down Journal: Biol Blood Marrow Transplant Date: 2004-04 Impact factor: 5.742
Authors: Aloysius Y L Ho; Antonio Pagliuca; Michelle Kenyon; Jane E Parker; Aleksandar Mijovic; Stephen Devereux; Ghulam J Mufti Journal: Blood Date: 2004-04-01 Impact factor: 22.113
Authors: H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas Journal: Am J Med Date: 1980-08 Impact factor: 4.965
Authors: Theo de Witte; David Bowen; Marie Robin; Luca Malcovati; Dietger Niederwieser; Ibrahim Yakoub-Agha; Ghulam J Mufti; Pierre Fenaux; Guillermo Sanz; Rodrigo Martino; Emilio Paolo Alessandrino; Francesco Onida; Argiris Symeonidis; Jakob Passweg; Guido Kobbe; Arnold Ganser; Uwe Platzbecker; Jürgen Finke; Michel van Gelder; Arjan A van de Loosdrecht; Per Ljungman; Reinhard Stauder; Liisa Volin; H Joachim Deeg; Corey Cutler; Wael Saber; Richard Champlin; Sergio Giralt; Claudio Anasetti; Nicolaus Kröger Journal: Blood Date: 2017-01-17 Impact factor: 22.113
Authors: Boglarka Gyurkocza; Jonathan Gutman; Eneida R Nemecek; Merav Bar; Filippo Milano; Aravind Ramakrishnan; Bart Scott; Min Fang; Brent Wood; John M Pagel; Joachim Baumgart; Colleen Delaney; Richard T Maziarz; Brenda M Sandmaier; Elihu H Estey; Frederick R Appelbaum; Barry E Storer; Hans Joachim Deeg Journal: Biol Blood Marrow Transplant Date: 2014-01-16 Impact factor: 5.742
Authors: Filippo Milano; Jonathan A Gutman; H Joachim Deeg; Eneida R Nemecek; Joachim Baumgart; Laurel Thur; Ann Dahlberg; Rachel B Salit; Corinne Summers; Frederick R Appelbaum; Colleen Delaney Journal: Blood Adv Date: 2020-07-28
Authors: T Sauer; G Silling; C Groth; F Rosenow; U Krug; D Görlich; G Evers; J Albring; R Besoke; R M Mesters; C Müller-Tidow; T Kessler; T Büchner; W E Berdel; M Stelljes Journal: Bone Marrow Transplant Date: 2015-01-19 Impact factor: 5.483
Authors: Eneida R Nemecek; Ralf A Hilger; Alexia Adams; Bronwen E Shaw; Deidre Kiefer; Jennifer Le-Rademacher; John E Levine; Gregory Yanik; Wing Leung; Julie-An Talano; Paul Haut; David Delgado; Neena Kapoor; Aleksandra Petrovic; Roberta Adams; Rabi Hanna; Hemalatha Rangarajan; Jignesh Dalal; Joseph Chewning; Michael R Verneris; Stacy Epstein; Lauri Burroughs; Evelio D Perez-Albuerne; Michael A Pulsipher; Colleen Delaney Journal: Biol Blood Marrow Transplant Date: 2018-05-09 Impact factor: 5.742
Authors: M Koenigsmann; J Casper; C Kahl; N Basara; H G Sayer; G Behre; S Theurich; M Christopeit; M Mohren; A Reichle; B Metzner; A Ganser; M Stadler; L Uharek; L Balleisen; A Hinke; R Hinke; D Niederwieser Journal: Bone Marrow Transplant Date: 2013-12-23 Impact factor: 5.483
Authors: Lauri M Burroughs; Eneida R Nemecek; Troy R Torgerson; Barry E Storer; Julie-An Talano; Jennifer Domm; Roger H Giller; Akiko Shimamura; Colleen Delaney; Suzanne Skoda-Smith; Monica S Thakar; K Scott Baker; David J Rawlings; Janet A Englund; Mary E D Flowers; H Joachim Deeg; Rainer Storb; Ann E Woolfrey Journal: Biol Blood Marrow Transplant Date: 2014-09-06 Impact factor: 5.742